WINT: Windtree Company Aggregate Debts

Windtree Therapeutics (WINT) is a pharmaceutical player in the cardiology sector facing the threat of bankruptcy and a liquidity shortage. This daily price chart illustrates metrics where the value stands at 0.00. The company's operations rely on developing therapies for critical heart failure. Despite holding patents, a weak economic moat persists due to constant FDA rejections and a lack of research funding.

WINT Windtree Therapeutics: Company Total Debt in the range 07/04/2022 - 09/06/2025

Comprehensive metric breakdowns and analytics for Windtree Therapeutics (WINT)

- price and consensus price forecast:

Market Price windtreetx.com|WINT - Analyst Consensus Forecast

- market capitalization data:

Market Capitalization Windtree|WINT - Total Company Value

- book capitalization data:

Accounting Value of a Share Windtree Therapeutics|WINT - Company Net Assets|Market Cap to Book Value Multiple windtreetx.com|WINT - Cumulative Company Assets

- debt and liquidity data:

Total Debt to Equity Ratio Windtree Therapeutics|WINT - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient windtreetx.com|WINT - Company Debts|Debt to Book Value Ratio Windtree

Analysis of all company metrics:WINT Windtree Therapeutics Inc.

Signature product of Windtree Therapeutics Inc.

This metric aggregates the total of all bank loans and bond issues, reflecting the level of debt burden and the risk of insolvency amid asset volatility. For Windtree Therapeutics (WINT), which invests in proprietary cardiovascular drugs, an analysis of total borrowed funds confirms strict control over clinical trial expenditures, ensuring capital stability and protection against credit risks.

Competitors of Windtree Therapeutics (WINT)